RT Journal Article
SR Electronic
T1 Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.07.22279684
DO 10.1101/2022.09.07.22279684
A1 Kanokudom, Sitthichai
A1 Chansaenroj, Jira
A1 Suntronwong, Nungruthai
A1 Assawakosri, Suvichada
A1 Yorsaeng, Ritthideach
A1 Nilyanimit, Pornjarim
A1 Aeemjinda, Ratchadawan
A1 Khanarat, Nongkanok
A1 Vichaiwattana, Preeyaporn
A1 Klinfueng, Sirapa
A1 Thongmee, Thanunrat
A1 Katanyutanon, Apirat
A1 Thanasopon, Wichai
A1 Arayapong, Jirawan
A1 Withaksabut, Withak
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Honsawek, Sittisak
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/09/09/2022.09.07.22279684.abstract
AB Objective To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax™) given as a third (booster) dose to individuals primed with different primary vaccine regimens.Methods Individuals primed with two doses of COVID-19 vaccines for at least 3 months were enrolled and assigned to five groups according to their primary vaccine regimens: CoronaVac, BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell response.Results Overall, 215 individuals were enrolled and boosted with the Covovax™ vaccine. The reactogenicity achieved was mild-to-moderate. Most participants elicited a high level of binding and neutralizing antibody responses against wild type and omicron variants following the booster dose. The 197 participants were classified by anti-N IgG. Of these, 141/197 (71.6%) were a seronegative population, and neutralizing activity and IFN-γ release were further monitored. A booster dose could elicit neutralizing activity to wild type and omicron variants by more than 95% and 70% inhibition at 28 days, respectively. The Covovax™ vaccine could elicit a cell-mediated immune response.Conclusion The protein subunit vaccine (Covovax™) can be proposed as a booster dose after two different priming dose regimens. It has strong immunogenicity and good safety profiles.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthe Thai Clinical Trials Registry (TCTR 20210910002)Funding StatementThis research was financially supported by the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 871/64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors